| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Yanwen Qin | |
| Guo-Ping Shi | |||
| P2860 | cites work | Cystatin C deficiency in human atherosclerosis and aortic aneurysms | Q22010733 |
| Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis | Q24305291 | ||
| Human cathepsin S: chromosomal localization, gene structure, and tissue distribution | Q24310666 | ||
| Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis | Q24314942 | ||
| Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading | Q24328923 | ||
| Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase | Q24336387 | ||
| Lysosomal cysteine proteases: facts and opportunities | Q24535678 | ||
| Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms | Q24623052 | ||
| Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases | Q24673558 | ||
| Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides | Q27639963 | ||
| A combined crystallographic and molecular dynamics study of cathepsin L retrobinding inhibitors | Q27657460 | ||
| Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease | Q28117779 | ||
| Structure and chromosomal assignment of the human cathepsin K gene | Q28117956 | ||
| Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis | Q28139155 | ||
| Distribution, activity and concentration of cathepsin B and cystatin C in the wall of aortic aneurysm | Q28144182 | ||
| Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms | Q28202574 | ||
| Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency | Q28284581 | ||
| Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2 | Q28304561 | ||
| Emerging roles for cysteine proteases in human biology | Q28306260 | ||
| Rat mast cell protease-I enhances immunoglobulin E production by mouse B cells stimulated with interleukin-4 | Q28365236 | ||
| Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor | Q28469107 | ||
| Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3 | Q28567588 | ||
| Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain | Q28572461 | ||
| Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5 | Q28573534 | ||
| Angiotensin II generation by mast cell alpha- and beta-chymases | Q28610117 | ||
| Cathepsin S required for normal MHC class II peptide loading and germinal center development | Q28611850 | ||
| Proteases involved in MHC class II antigen presentation | Q28611916 | ||
| Macrophage differentiation to foam cells | Q30438116 | ||
| Optical Visualization of Cathepsin K Activity in Atherosclerosis With a Novel, Protease-Activatable Fluorescence Sensor | Q58816186 | ||
| Cysteine Proteases and Their Inhibitors | Q61066438 | ||
| Atherosclerotic Abdominal Aortic Aneurysm and the Interaction Between Autologous Human Plaque-Derived Vascular Smooth Muscle Cells, Type 1 NKT, and Helper T Cells | Q61913033 | ||
| Perivascular Mast Cells Promote Atherogenesis and Induce Plaque Destabilization in Apolipoprotein E–Deficient Mice | Q63258329 | ||
| Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. | Q64885339 | ||
| "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. | Q64932386 | ||
| Synthesis of cysteine proteinase inhibitors structurally based on the proteinase interacting N-terminal region of human cystatin C | Q68920138 | ||
| Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells | Q72591955 | ||
| Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation | Q73009399 | ||
| Focal dermal-epidermal separation and fibronectin cleavage in basement membrane by human mast cell tryptase | Q73036428 | ||
| Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease | Q73047154 | ||
| Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo | Q73077056 | ||
| Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis | Q73098437 | ||
| Mast cells and susceptibility to experimental atherosclerosis | Q73167379 | ||
| Mast cells in human atherosclerosis | Q73513175 | ||
| Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima | Q74078800 | ||
| Structural basis for different inhibitory specificities of human cystatins C and D | Q74377975 | ||
| Mast cell tryptase stimulates both human dermal fibroblast proliferation and type I collagen production | Q74452712 | ||
| Differences in tissue angiotensin II-forming pathways by species and organs in vitro | Q77310292 | ||
| Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus | Q77327400 | ||
| Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta | Q77894894 | ||
| Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment | Q79401048 | ||
| Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha | Q80198017 | ||
| The significance of chymase in the progression of abdominal aortic aneurysms in dogs | Q80412848 | ||
| Mast cells promote atherosclerosis by releasing proinflammatory cytokines | Q80422792 | ||
| Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer | Q80726283 | ||
| High prevalence of circulating CD4+CD28- T-cells in patients with small abdominal aortic aneurysms | Q81676402 | ||
| Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats | Q94608691 | ||
| Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro | Q43517008 | ||
| Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice | Q43560207 | ||
| Cathepsin K, osteoclastic resorption, and osteoporosis therapy | Q43755557 | ||
| Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein | Q43772758 | ||
| A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts | Q43790817 | ||
| Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction | Q44014729 | ||
| Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells | Q44050000 | ||
| Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta | Q44100854 | ||
| Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol | Q44249768 | ||
| Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta | Q44250871 | ||
| A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury | Q44285586 | ||
| Chymase inhibitor improves survival in hamsters with myocardial infarction | Q44398819 | ||
| Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. | Q44442851 | ||
| Tryptase levels in patients after acute coronary syndromes: the potential new marker of an unstable plaque? | Q44549571 | ||
| Impact of chymase inhibitor on cardiac function and survival after myocardial infarction | Q44653123 | ||
| Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells | Q44677550 | ||
| Increased chymase in livers with autoimmune disease: colocalization with fibrosis | Q44699445 | ||
| An antiarrhythmic effect of a chymase inhibitor after myocardial infarction | Q44733099 | ||
| A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters | Q44762756 | ||
| Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy | Q44904231 | ||
| Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes | Q45036841 | ||
| Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide | Q45103201 | ||
| Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice | Q45226535 | ||
| Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis | Q45230800 | ||
| Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis | Q45232044 | ||
| Mast cell tryptase: a new biomarker in patients with stable coronary artery disease | Q45253410 | ||
| Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis | Q46190563 | ||
| Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice | Q46256442 | ||
| Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain | Q46406006 | ||
| Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. | Q46624696 | ||
| Increased serum cathepsin S in patients with atherosclerosis and diabetes | Q46685170 | ||
| Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice | Q46740608 | ||
| Azepanone-based inhibitors of human cathepsin L. | Q46775748 | ||
| Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. | Q46859366 | ||
| Destabilizing role of cathepsin S in murine atherosclerotic plaques | Q46893001 | ||
| Mast cell beta-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities | Q46975971 | ||
| Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. | Q47334929 | ||
| Human chymase, an enzyme forming novel bioactive 31-amino acid length endothelins | Q47683663 | ||
| Cerebral vasospasm: presence of mast cells in human cerebral arteries after aneurysm rupture | Q50938999 | ||
| Laminar shear stress inhibits cathepsin L activity in endothelial cells. | Q51198411 | ||
| A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. | Q51787069 | ||
| Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. | Q51941132 | ||
| Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. | Q52574343 | ||
| Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE−/− mice | Q53307544 | ||
| Cathepsin-cleaved Bid promotes apoptosis in human neutrophils via oxidative stress-induced lysosomal membrane permeabilization. | Q53574092 | ||
| An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats | Q53597230 | ||
| Degradation of apolipoprotein B-100 by lysosomal cysteine cathepsins. | Q53599405 | ||
| Mast cells associate with neovessels in the media and adventitia of abdominal aortic aneurysms. | Q54478166 | ||
| In vivo imaging of proteolytic activity in atherosclerosis | Q57188411 | ||
| Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis | Q57420159 | ||
| Role of smooth muscle cells in the initiation and early progression of atherosclerosis | Q30438867 | ||
| Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts | Q30491065 | ||
| A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. | Q33210291 | ||
| Lysosomal cathepsin initiates apoptosis, which is regulated by photodamage to Bcl-2 at mitochondria in photodynamic therapy using a novel photosensitizer, ATX-s10 (Na). | Q33248868 | ||
| Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L | Q33327656 | ||
| Tryptase promotes human monocyte-derived macrophage foam cell formation by suppressing LXRalpha activation | Q33530011 | ||
| Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes | Q33561251 | ||
| The lysosomal cysteine proteases | Q33689936 | ||
| Cathepsin L Inhibition Prevents Murine Autoimmune Diabetes via Suppression of CD8+ T Cell Activity | Q33705115 | ||
| Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice | Q33947334 | ||
| Cathepsin L is essential for onset of autoimmune diabetes in NOD mice | Q34014524 | ||
| Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. | Q34020306 | ||
| The fibrinogenolytic activity of purified tryptase from human lung mast cells | Q34168262 | ||
| Local angiotensin II-generating system in vascular tissues: the roles of chymase | Q34284663 | ||
| Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis | Q34320916 | ||
| Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. | Q34325457 | ||
| Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages. | Q34326413 | ||
| Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. | Q34343810 | ||
| Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation | Q34372297 | ||
| Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages | Q34385281 | ||
| The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics | Q34416331 | ||
| Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation | Q34478046 | ||
| Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases | Q34487589 | ||
| Extracellular proteolysis in the development and progression of atherosclerosis | Q34649806 | ||
| Protease inhibitors in the clinic. | Q34652378 | ||
| Cathepsin L activity controls adipogenesis and glucose tolerance | Q34654358 | ||
| Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population | Q34756920 | ||
| Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases | Q34769315 | ||
| Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice | Q34967612 | ||
| Lysosomal cysteine proteases (cathepsins): promising drug targets. | Q35055535 | ||
| Atherosclerosis and extracellular matrix | Q35626748 | ||
| Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms | Q35635554 | ||
| Lysosomal cysteine proteases in atherosclerosis | Q35792643 | ||
| Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture | Q35884657 | ||
| Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice | Q36025276 | ||
| Proteinaceous cysteine protease inhibitors | Q36072062 | ||
| Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages | Q36368869 | ||
| Lysosomal cysteine proteases: structure, function and inhibition of cathepsins | Q36402252 | ||
| Cathepsin-regulated apoptosis | Q36406709 | ||
| Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport | Q36418492 | ||
| Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice | Q36503124 | ||
| Cysteine cathepsins: multifunctional enzymes in cancer | Q36600996 | ||
| Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress | Q36618016 | ||
| Role of cathepsin K in normal joints and in the development of arthritis | Q36737790 | ||
| Emerging roles of cysteine cathepsins in disease and their potential as drug targets. | Q36740577 | ||
| Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 | ||
| Mast cell proteases | Q36942528 | ||
| Cysteine cathepsin proteases as pharmacological targets in cancer | Q37013943 | ||
| Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation | Q37181208 | ||
| Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice | Q37330290 | ||
| Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase | Q37353512 | ||
| Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor | Q37368189 | ||
| Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation | Q37375537 | ||
| Cathepsin S activity regulates antigen presentation and immunity | Q37382422 | ||
| Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells | Q37384330 | ||
| Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm | Q37582156 | ||
| Recent advances in the design of cathepsin S inhibitors | Q37718822 | ||
| Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis | Q39737467 | ||
| Heparin enhances serpin inhibition of the cysteine protease cathepsin L. | Q39767236 | ||
| Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study | Q39876880 | ||
| Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: role in cell migration | Q40247795 | ||
| Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. | Q40310101 | ||
| Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice | Q41855757 | ||
| Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells | Q42480510 | ||
| Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs | Q42705355 | ||
| Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response | Q42773864 | ||
| Cathepsin K gene disruption does not affect murine aneurysm formation. | Q43272423 | ||
| P433 | issue | 3 | |
| P921 | main subject | mast cell | Q191989 |
| cardiovascular disease | Q389735 | ||
| P304 | page(s) | 338-350 | |
| P577 | publication date | 2011-05-12 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases | |
| P478 | volume | 131 |
| Q35148852 | Association between SNP rs1800875, serum chymase and immunoglobulin E levels in patients with coronary heart disease |
| Q47549875 | Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis. |
| Q37593416 | Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy |
| Q36560578 | Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction |
| Q46282528 | Cathepsin L deficiency results in reactive oxygen species (ROS) accumulation and vascular cells activation |
| Q33789216 | Cathepsin L promotes Vascular Intimal Hyperplasia after Arterial Injury |
| Q37297985 | Cathepsin L protects mice from mycoplasmal infection and is essential for airway lymphangiogenesis. |
| Q37187482 | Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction |
| Q35606010 | Cathepsins: a new culprit behind abdominal aortic aneurysm. |
| Q47696129 | Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases |
| Q36599238 | Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms. |
| Q52573372 | Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials. |
| Q30528440 | Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice |
| Q58702250 | Dilating Vascular Diseases: Pathophysiology and Clinical Aspects |
| Q37226344 | Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice |
| Q91709813 | Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples |
| Q35868633 | Mast cell stabilization: novel medication for obesity and diabetes |
| Q39159480 | Myocardial proteases and cardiac remodeling. |
| Q58551243 | Papain Ameliorates the MPAs Formation-Mediated Activation of Monocytes by Inhibiting Cox-2 Expression via Regulating the MAPKs and PI3K/Akt Signal Pathway |
| Q34635528 | Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. |
| Q35173790 | Single nucleotide polymorphisms of cathepsin S and the risks of asthma attack induced by acaroid mites |
Search more.